Seven-day vonoprazan-based triple therapy as first-line Helicobacter pylori treatment in comparison with extended sequential therapy.

Yu-Tse ChiuFu-Jen LeeChen-Ya KuoYang-Chao LinKai-Shun LiangLiang-Wei TsengYu-Tsung ChenChi-Yang Chang

Published in: JGH open : an open access journal of gastroenterology and hepatology (2023)

regimen alternative to current standard treatment, with the advantages of simplicity, short treatment duration, low pill burden, and fewer major adverse effects.

Keyphrases

helicobacter pylori
stem cells
combination therapy
risk factors
clinical evaluation